By employing nanocarriers as a drug delivery method, such as niosomes, it is possible to address the drawbacks of conventional drug delivery systems, such as undesirable pharmacokinetics, distribution, and drug degradation. Niosomes are tiny lamellar structures that are biodegradable, biocompatible, and non-immunogenic. They are also very low in toxicity and offer high biocompatibility. The amphiphilic bilayer structure of niosomes has polar and nonpolar regions. The key benefit of employing niosomes as a drug delivery system is that it may be used to administer a range of medications since it has the potential to entrap hydrophilic, lipophilic, and amphiphilic medications. Niosomes are more superior to liposomes as they are more physically and chemically stable than liposomes as niosomes are less vulnerable to chemical degradation or oxidation than phospholipids. The major application of niosomes is the controlled and the targeted release of the drugs. Niosomes have been thoroughly investigated in recent years for their potential to function as a vehicle for the transport of medications, antigens, hormones, and other bioactive molecules. Niosomes have also been employed to address the issues of drug insolubility, instability, and fast degradation. To increase the therapeutic efficacy of some anti-inflammatory medications, such as flurbiprofen and piroxicam, and sex hormones, such as estradiol and levonorgestrel, niosomes are widely used in transdermal administration. Better drug concentration at the site of action is also provided by this vesicular system when drugs are delivered topically, parenterally, or orally. Niosomes' sustained release activity can be used to deliver medicines with poor therapeutic indices and water solubilities.
